Suman Chowdhury1, Suresh Kumar1. 1. University School of Biotechnology, Guru Gobind Singh Indraprastha University, Dwarka, New Delhi.
Abstract
Depletion of acetylcholine in the central nervous system (CNS) is responsible for memory loss and cognition deficit. Enzyme acetylcholinesterase (AChE) is responsible for destruction of acetylcholine (Ach) in the brain. Many herbal plant extracts have been investigated for their potential use in the treatment of Alzheimer's disease (AD) by inhibiting AChE and upregulating the levels of Ach. The current study investigated the anti-acetylcholinesterase (AChE) activity of an aqueous extract of Unicaria tomentosa bark which has not been reported so far in the literature. The in vitro study of an aqueous extract of U. tomentosa showed maximum inhibition of 76.2±0.002 % at 0.4mg/ml of final concentration with an IC50 = 0.112 mg/ml. The mechanism of inhibition was elucidated by kinetic study which showed mixed type of inhibition, this might be due to the presence of various phytoconstituents such as oxindole alkaloids present in an aqueous extract. Based on molecular structure of phytoconstituents obtained from U. tomentosa known from the relevant literature, in-silico molecular docking study was performed against AChE protein to validate the results.
Depletion of acetylcholine in the central nervous system (CNS) is responsible for memory loss and cognition deficit. Enzyme acetylcholinesterase (AChE) is responsible for destruction of acetylcholine (Ach) in the brain. Many herbal plant extracts have been investigated for their potential use in the treatment of Alzheimer's disease (AD) by inhibiting AChE and upregulating the levels of Ach. The current study investigated the anti-acetylcholinesterase (AChE) activity of an aqueous extract of Unicaria tomentosa bark which has not been reported so far in the literature. The in vitro study of an aqueous extract of U. tomentosa showed maximum inhibition of 76.2±0.002 % at 0.4mg/ml of final concentration with an IC50 = 0.112 mg/ml. The mechanism of inhibition was elucidated by kinetic study which showed mixed type of inhibition, this might be due to the presence of various phytoconstituents such as oxindole alkaloids present in an aqueous extract. Based on molecular structure of phytoconstituents obtained from U. tomentosa known from the relevant literature, in-silico molecular docking study was performed against AChE protein to validate the results.
Alzheimer’s disease (AD) is a neurodegenerative disease and
the most common form of dementia afflicting approximately 35
million people worldwide [1]. AD is an acquired, progressive
illness with gradual deterioration of central nervous system
until death. One in ten persons over 65 and nearly half of adults
over 85 years have AD [2]. The clinical symptoms associated
with AD include impaired ability to learn new information and
recall old information, a decline in language function,
dyspraxia, agnosia and impairment of executive functioning
[3]. Neuropathological changes include neuronal reduction,
neurofibrillary tangles, senile neurotic plaques and a variable
amyloid angiopathy [4]. Neurochemical changes occur,
including a marked reduction in the levels of acetylcholine and
other neurotransmitters and neuromodulators [5]. Several
mechanisms have been proposed to explain the cause of the
disease including those of the misfolded and aggregated
proteins of amyloid beta and tau [6]. But, the most conventional
theory is “cholinergic hypothesis”. This hypothesis proposes
that there is decline in concentration of the neurotransmitter,
acetylcholine (Ach) mainly due to the action of cholinesterase
enzymes in CNS [7,8]. Therefore, the current therapeutic
strategies mainly involve focusing on anti-cholinesterase
inhibitors.There are limited therapeutic options available for AD. The
available drugs in the market for symptomatic treatment have
several drawbacks such as side effects, low bioavailability, high
cost and requirement of weekly blood monitoring [9]. In view
of these limitations, the present study focuses on an aqueous
extract of Uncaria tomentosa, commonly known as cat’s claw for
AChE inhibition activity. U. tomentosa is a large, woody vine
that is indigenous to the Amazon rainforest [10]. U. tomentosa
bark has been used traditionally in Peruvian medicine to treat
gastritis, asthma and arthritis inflammatory conditions [11].
The herb has also been shown to possess antioxidant properties [12].
In-vivo and in-vitro work has also shown that U. tomentosa
extract alone and in combination with at least one of Ginkgo
biloba, rosemary, gotu kola and bacopin, prevent the formation
beta-amyloid plaques and the extract alone improves memory
function in mice with experimental amnesia [13-14]. Of
particular interest is the significant binding of an oxindole
alkaloid (mitraphylline) with beta-amyloid 1-40 [15]. Number
of biologically active compounds such as quinovic acid
glycosides, triterpenes, flavonoids (rutin and quercetin),
phytosteroids (b-sitosterol, stigmasterol, and campesterol), and
catechins are present in different parts of the plant. Out of these
compounds, the most pharmacologically active compounds are
tetracyclic oxindole such as rhyncophylline and
isorhyncophylline and pentacyclic oxindole such as
speciophylline, uncarine F, uncarine C, uncarine E,
mitraphylline, isomitraphylline, pteropodine, and
isopteropodine [16,17]. The present study investigates in-vitro
anti-AChE activity of an aqueous extract of U. tomentosa and insilico
molecular docking study of active tetra-and pentacyclic
oxindole constituents, to investigate the binding interactions
with acetylcholinesterase enzyme.
Methodology
Plant material and extraction
The bark of U. tomentosa was purchased from a local store in
Delhi, India and authenticated by a local botanist and a voucher
specimen (USBT/SK/CC011) was stored in the herbarium at
University School of Biotechnology, GGSIP University, Dwarka
Sec- 16C, New Delhi-110075. Aqueous extracts was prepared by
boiling 10 gm of air dried bark powdered of herb in 50 ml (1:5
w/v) of boiling distilled water for half an hour, from which
freeze dried extracts were prepared using lyophilizer (Heto,
Thermo scientific) and subsequently diluted in water to the
desired concentrations.
In-vitro assay
The aqueous extract of U. tomentosa was examined for AChE
inhibitory activity using Ellman’s assay [18] at various
concentrations (0.4 - 0.025 mg/ml) and was dissolved in a 0.1 M
phosphate buffer, pH8. To a flat bottom 96-well plate, typical
run consisted of, 5 μl of Acetylthiocholine (ATCh) (0.5 mM), 5
μl of 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB) (0.03 mM) and
5 μl of the test extract solution at the different concentrations
evaluated, which were mixed and incubated for 10 min at 30
μC. Then, 5 μl of AChE (0.3 U/ml) solution was added to the
initial mixture to start the reaction and then absorbance was
determined at 412nm (SpectraMax M2, 96-well plate reader). A
control run contained all the aforementioned constituents with
exception of the test extract. All experiments were performed in
triplicate with two replicates. The concentration of the tested
extract that inhibited the hydrolysis of substrate ATCh by 50%
(IC50) was determined by linear regression analysis. Kinetic
analysis was also performed using Line weaver Burk method,
where enzyme AChE was pre-incubated with different ATCh
concentration ranging from 0.5-0.0625mM in the presence and
absence (control) of different concentration of U. tomentosa
ranging from 1- 0.0625 mg/ml.
Preparation of protein target structure
Acetylcholinesterase complexed with (-)-Galantamine (PDBID-
4EY6, resolution 2.4 Å) was retrieved from the Protein Data
Bank and further modified for Schrodinger’s Glide docking
calculations. For Glide v6.9 calculations, pdb file was imported
to Maestro v10.4 and the protein was prepared using Protein
Preparation Wizard (PPW) (Figure 1). All the water molecules
were deleted except the seven water molecules, which were
directly interacting with the important residues of the active
site. Active site was defined using the (-)-Galantamine
(inhibitor) from co-crystallized structure. The docking protocol
was optimized by generating same crystal binding
conformation of (-)-Galantamine with a root mean square
deviation (RMSD) of 0.1273 Å [19].
Figure 1
Three-dimensional structure of human acetyl-cholinesterase enzyme (PDBID 4EY6)
Preparation of ligands
3-D structures of U. tomentosa active constituents in .sdf format
were retrieved from Pubchem database (Figure 2). LigPrep
module of Schrodinger was used for ligand preparation [20].
Figure 2
Two-dimension structure of A-Galantamine, B-Rhyncophylline, C-Isorhyncophylline, D-Unicarine E, E-Tacrine
Ligand docking
Prepared protein and ligands was docked using Glide (Gridbased
Ligand Docking with Energetics) v6.9 module in
Schrodinger. Extra precision module of Glide algorithm was
used to dock ligand to the active site. All the Glide docking
runs were performed on Intel® Core™ i7-3770 CPU @ 3.40GHz
of HP origin, with 4GB RAM, Windows 8Pro operating system.
The output from Glide was studied in XP visualizer and images
were taken to study the interaction.
Results & Discussion:
Enzymatic inhibition study
An aqueous extract of U. tomentosa plant inhibited AChE in a
concentration dependent manner (0.4 to 0.02mg/ml). The
aqueous extract showed maximum inhibition of enzyme (76.2±0.002%) at 0.4mg/ml final concentration. The IC50 value
obtained from inhibition curve was 0.112 mg/ml (Figure 3).
Kinetic study
The Lineweaver-Burk (LB) plot was used to study enzyme
inhibition kinetics. The mode of inhibition displayed by LB plot
was mixed inhibition (Figure 4). At the lower concentrations of
an extract the plot suggested uncompetitive inhibition and at
higher concentrations of extract showed non-competitive mode
of inhibition. Hence, overall conclusion drawn from LB plot
was mixed type of inhibition. The mixed mode of inhibition is
very common in traditional medicinal plants due to the
presence of different type of compounds in the extract [21].
Previous studies have suggested that for AChE induced betaamyloid
aggregation can be overcome by mixed or non
competitive mode of inhibition, as these inhibitors bind to the
peripheral anionic sites and therefore inhibiting beta-amyloid
accumulation and aggregation [22]. Apart from antioxidant,
anti-inflammatory and immunomodulatory properties U.
tomentosa has shown to potential action on beta-amyloid plaque
formation.
Figure 4
Line weaver-Burk plot of initial velocity of AChE against ATCh concentrations for control and different concentrations of
U. tomentosa.
Molecular docking study
For the selected 10 phytoconstituents 27 poses were generated
after ligprep, out of which the poses with better glide score and
lower glide energy for each ligand was selected. Analysis of
molecular docking result showed that all the phytoconstituents
have their Glide score in the range of -10.5 to -5.96 Kcal/mol
and Glide energy -32.934 to -12.399 Kcal/mol.
Isorhynchophylline, Rhynchophylline and Unicarine E showed
the best Glide score of -10.05, -9.05 and -9.50 Kcal/mol
respectively. When compared with Tacrine (-6.99 Kcal/mol), all
the phytoconstituents showed more and comparable Glide
score except Isopteropodine, Mitraphylline and
Isomitraphylline. Although, previous studies shows significant binding of Mitraphylline to beta-amyloid (1-40) here it shows
lower Glide score (-6.00 Kcal/mol). It was also observed that
only Isorhynchophyllin showed Glide score as good as
standard drug Galantamine, followed by Rhynchophylline.
Among, the top three phytoconstituents on the basis of Glide
score, Uncarine E has the lowest Glide energy (-32.934
Kcal/mol) and no hydrogen bonding interaction. While,
Rhynchophylline with -12.399 Kcal/mol of Glide energy, shows
two hydrogen bonding interaction with residues His447 (1.92Å
bond length) and Phe295 (2.52Å) and one pi-pi interaction with
Trp86. Whereas, Isorhynchophylline with Glide energy of -
27.436 Kcal/mol shows no hydrogen bonding interaction
(Figure 5&6). To sum up all the phytoconstituents of U.
tomentosa more or less shows a good binding affinity towards
the active site of the acetylcholinesterase, on the basis of Glide
score and Glide energy (Table 1).
Figure 5
Binding mode between AChE enzyme and different ligand (A-Galantamine, B-Rhyncophylline, C-Isorhyncophylline, DUnicarine
E, E-Tacrine).
Figure 6
Ligprot representation of interaction between different residues of AChE enzyme and ligand (A - Galantamine, B -
Rhyncophylline, C - Isorhyncophylline, D - Unicarine E, E - Tacrine).
Table 1
Interactions in the docked complexes of ligands with AChE enzyme as obtained through Glide docking
S. No
Ligand
Glide score (Kcal/mol)
Glide Energy (Kcal/mol)
No. H-bonds
Interacting residues
Bond length (Å)
POSITIIVE CONTROL
1
Tacrine
-6.99
-29.77
1
Tyr337
2.56
2
Galantamine
-10.98
-43.85
3
Tyr133
2.01
Tyr337
2.05
PHYTOCONSTITUENTS
1
Isorhynchophylline
-10.05
-27.436
0
-
-
Phe295 - Trp86 (π- π)
2.52
2
Uncarine E
-9.5
-32.934
-
-
-
3
Rhynchophylline
-9.05
-12.399
2
His447
1.92
4
Uncarine C
-7.2
-20.377
Tyr337- Tyr341 (π- π)
5
Pteropodine
-7.07
-29.155
1
His447
2.62
6
Uncarine F
-6.91
-29.116
1
His447
2.49
7
Speciophylline
-6.68
-32.934
2
Tyr337,
2.02
Thr83
2.79
8
Mitraphylline
-6
-28.04
0
-
-
9
Isomitraphylline
-6.16
-29.606
2
Tyr337,
2.42
His447 - Tyr337 (π- π)
10
Isopteropodine
-5.96
-19.107
0
-
-
Conclusion:
U. tomentosa is an interesting herb in terms of its potential use
in the treatment of AD. Previous in-vitro study showed that U.
tomentosa extract prevents beta-amyloid plaque formation and
in in-vivo improves memory function in mice. Our study
revealed that an aqueous extract of U. tomentosa exhibits potent
anti-AChE activity might be due to the presence of active
constituent’s oxindol alkaloids. Kinetic studies have indicated
that an aqueous extract showed mixed mode of inhibition due
to the presence of other phytoconstituents, which need further
analysis. Above finding was validated with molecular docking
study of its active constituents. Out of all the alkaloidsIsorhynchophylline, Rhynchophylline and Unicarine E showed
highest Glide score and lowest Glide energy as good as that of
Galantamine the standard drug approved by food and Drug
Administration (FDA). Moreover, U.Tomentosa antioxidant,
antiinflammatory, immuno-modulatory, anti AChE and
potential amyloid plaque prevention properties may have
combined benefits for the treatment of AD. These findings add
to a body of evidence suggesting further evaluation of the effect
of aqueous extracts of U. tomentosa and its constituents.
Authors: Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2012-05 Impact factor: 3.685
Authors: Teresa Frackowiak; Tomasz Baczek; Kaliszana Roman; Beata Zbikowska; Michał Gleńsk; Izabela Fecka; Wojciech Cisowski Journal: Z Naturforsch C J Biosci Date: 2006 Nov-Dec
Authors: Mary E Heitzman; Catherine C Neto; Elizabeth Winiarz; Abraham J Vaisberg; Gerald B Hammond Journal: Phytochemistry Date: 2005-01 Impact factor: 4.072